The vertically integrated cannabis company with headquarters, cultivation, and processing facilities in Akron said it has reached a settlement with the state of Ohio that resolves years of litigation and, as a result, enables the business to open two new marijuana dispensaries in Northeast Ohio.
“We would like to express our sincere gratitude to the leadership and staff of the Division of Cannabis Control, who have endeavored to amicably resolve these cases despite undertaking a mountain of work readying the state for its new adult-use program,” said Klutch founder and CEO Adam Thomarios in a statement. “We are thrilled to be able to finally put these cases behind us and are ready to get to work preparing these stores for our patients and future adult-use customers.”
One of these two shops, according to the company, will be in downtown Cleveland at 300 Prospect Ave. E.
The long-vacant storefront there was once home to Record Rendezvous, a legendary music shop that occupied the space between 1945 and 1987. The shop’s owner, Leo Mintz, is credited with helping coin the term “rock ‘n’ roll,” thereby playing a role in establishing Cleveland’s heritage as a rock ‘n’ roll city.
Klutch currently operates marijuana dispensaries in Lorain and Canton that have been operating under the brand name “The Citizen by Klutch.”
Its future Cleveland store, though, which is a stone’s throw from East 4th Street and Rocket Mortgage FieldHouse, will be the most high-profile shop in the Klutch footprint.
Thomarios describes it at Klutch’s future flagship store, noting its design will pay “homage to its unique musical heritage.”
“Our Cleveland location is located right in the heart of downtown Cleveland’s entertainment district and is a historical landmark with an amazing cultural connection to the city and region,” said Klutch vice president Pete Nischt. “It’s a shame that it’s been vacant for so long, but we are on a mission to restore it to its former glory. We want this next iteration of the building to honor its past while being the best representation of our brand, company, and vision thus far.”
Klutch said its other new store will be at 10650 Northfield Road in Northfield Village, which is across the street from the MGM Northfield Park racino and “uniquely positioned to serve Northern Summit County and surrounding communities.”
The settlement enabling these new dispensaries follows three lawsuits that Klutch brought against the Ohio Board of Pharmacy challenging the results of its processes for awarding dispensary licenses.
These suits were related to applications to operate retail shops at locations in Akron, Cleveland Heights, and Euclid.
The first lawsuit dates back to the state’s inaugural round of medical marijuana dispensary licensing, a process known as RFA I. (RFA stands for “request for applications.”)
Applications for RFA I opened in 2017, and permit winners were selected in that round via a scoring system that rated applications on a series of criteria.
Klutch challenged scoring discrepancies between it and other applicants as it appealed the results on the application for its proposed Akron shop.
Klutch’s other two suits stem from the state’s second dispensary application process or RFA II.
RFA II applications opened in 2021. However, the state switched its approval process from a scoring dynamic to a lottery system — in large part due to litigation that resulted from RFA I. Applications still had to meet particular criteria to be eligible, but winners were ultimately selected through a drawing conducted by the Ohio Lottery Commission.
“In one case, we challenged a rule that, as applied, prevented the award of a license. That rule has since been reinterpreted to match the controlling statute,” Nischt said. “In the other case, we challenged what we felt was the non-application of a requirement that resulted in another applicant winning a license at a site we applied on.”
Klutch’s suits were filed against the board of pharmacy as that agency was previously the primary regulator for dispensaries under the Ohio Medical Marijuana Control Program. All other business activity was regulated by the Ohio Department of Commerce.
At the beginning of 2024, the state removed the Board of Pharmacy as a cannabis regulator and flattened the regulatory dynamic from two agencies to one. The state’s primary marijuana industry regulator is now the Division of Cannabis Control, or DCC, which operates within the commerce department.
As far as how this settlement was achieved, Nischt said the transition to DCC “provided all involved with a good opportunity to take a step back and evaluate everything.”
“Despite how busy they were, the DCC made time to try to resolve these issues with us. Our settlement resolved all three cases and resulted in the award of two licenses,” Nischt said. “At the end of the day, we are satisfied with the outcome, appreciative of the time spent working through these issues with us, and are excited to show these new locations what we are made of.”
Crain’s has reached out to DCC officials for comments on the settlement with Klutch.
Klutch must complete build-outs for its new shops in Cleveland and Northfield Village ahead of regulators allowing them to serve the public.
Nischt said the expectation is that the Cleveland store will come online first but that the company expects both to be operational in the first quarter of 2025.
Meanwhile, in conjunction with the announcement about this settlement and its new dispensaries, Klutch said it will rebrand its retail operation from “The Citizen by Klutch” to simply “Klutch Cannabis.” The company said more details about this rebrand will come in the fall as official rules for the adult-use program are finalized.
Massachusetts regulators will require cannabis businesses to use a single laboratory for all compliance testing in an effort to prevent companies from shopping around for favorable test results.
The state’s Cannabis Control Commission voted 3-0 to require licensed businesses submit testing samples to one independent laboratory starting April 1, 2025, according to an administrative order advanced Thursday. The new rule is meant to close loopholes that some say have allowed companies to shop around for labs to juice their numbers for market share.
“This administrative order continues our mission of being a strong regulator,” Acting Executive Director Debbie Hilton-Creek said in a statement.
Under current rules, companies can split testing among multiple labs. The practice has led some facilities to report suspiciously high THC levels or overlook contamination to attract business.
The commission’s enforcement team said the changes would reduce risks of noncompliant products reaching consumers and improve audit capabilities. The move follows a November listening session in which testing concerns were raised, according to the announcement.
If an original testing lab needs to subcontract work, they must first obtain commission approval and demonstrate they are “incapable of performing certain required tests due to a hardship.” Labs also can only subcontract with one other facility at a time.
“The commission shall only approve subcontracting agreements when the Originating Independent Testing Laboratory is incapable of performing certain required tests due to a hardship relative to its facilities, instrumentation, personnel, or required consumable materials or in the event of an actual or potential conflict of interest,” according to the order.
Results must be uploaded to the state’s tracking system within 72 hours, with all certificates of analysis containing the complete testing results, including any subcontracted work, it said.
The commission will also begin publishing THC test results on its public data platform and establishing regular meetings with licensed laboratories to improve oversight.
The commission thus far has struggled to implement effective testing oversight. Earlier this year, the agency contracted with a private lab for a “secret shopper” program to verify retail products’ test results, Green Market Report previously reported. Unlike other major cannabis markets such as California and Colorado, Massachusetts lacks a state reference lab to independently verify commercial lab results.
Analysis of testing data by MCR Labs found that across multiple states, laboratories reporting higher THC concentrations tend to increase their market share while those reporting average failure rates lose business, according to Chemical & Engineering News.
Florida-based Cansortium (CSE: TIUM.U) (OTCQB: CNTMF), which does business as Fluent, has finalized its megamerger with New York-based RIV Capital, (CSE: RIV) (OTC: CNPOF), creating a new multistate operator that has a footprint in four states with 42 operational dispensaries.
The move gives Cansortium immediate access to New York, one of the fastest-growing legal marijuana markets in the nation, along with its existing portfolio of cannabis shops and grows in its home state, Pennsylvania and Texas. The company now owns eight total cultivation and processing facilities, which it said in a press release would allow it to bolster the Fluent brand even more going forward.
The company reportedly has $33 million in the bank with which to finance further acquisitions, it said in a Thursday announcement.
Another major winner in the deal is Scotts Miracle-Gro, which has a sizable stake in RIV Capital through its subsidiary The Hawthorne Collective. Existing shares will be converted into 1.245 shares of the newly formed Fluent, eliminating $160 million in company debt.
Shareholders of Cansortium will own 51.25% of the new Fluent, while shareholders of RIV Capital will own 48.75%, the company said. The company will continue trading under Cansortium’s existing ticker symbols on the Canadian Securities Exchange and the Over-The-Counter markets.
Cansortium CEO Robert Beasley will continue to lead the new company, and RIV Capital interim CEO David Vautrin will serve as the new company’s chief commercial officer.
Beasley said in the release that Fluent intends to scale up wholesale operations in New York to boost its Moods brand of marijuana products and “gain additional shelf space in dispensaries across the state,” which he said has “immense potential.”
The merger could prove key to the long-term prospects for both Cansortium and RIV Capital. Cansortium posted an $11.7 million net loss for the third quarter of 2024, and RIV Capital reported a $63.4 million net loss for the same period.
“Looking ahead, we remain focused on sustainable, long-term growth and will continue to drive efficiencies across all areas of the business to achieve our profitability and cash generation goals,” Beasley said.
Greenway Greenhouse Cannabis Corp. entered into an asset purchase agreement to acquire all of Choice Growers’ consumer packaged goods brands, SKUs and listings of the brands, trademarks, goodwill and other associated intellectual property. This acquisition encompasses all of Choice Growers’ brands, including Grapefruit God Bud (also known as Grape God), The Jeffrey, Watermelon Pebbles, Pink Lemonade, Duke Nukem, Tangerine Dream and Blackberry Cheesecake.
Innocan Pharma Corp. intends to complete a non-brokered private placement of up to 3.5 million units of the company at a price of C$0.20 per unit for gross proceeds up to C$700,000 plus 15% overallotment options. The offering is expected to close on or around Dec. 31.